WO2002081507A3 - Interferon gamma polypeptide variants - Google Patents

Interferon gamma polypeptide variants Download PDF

Info

Publication number
WO2002081507A3
WO2002081507A3 PCT/DK2002/000226 DK0200226W WO02081507A3 WO 2002081507 A3 WO2002081507 A3 WO 2002081507A3 DK 0200226 W DK0200226 W DK 0200226W WO 02081507 A3 WO02081507 A3 WO 02081507A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide variants
interferon gamma
variants
treatment
gamma polypeptide
Prior art date
Application number
PCT/DK2002/000226
Other languages
French (fr)
Other versions
WO2002081507A2 (en
Inventor
Anne Dam Jensen
Original Assignee
Maxygen Holdings Ltd
Anne Dam Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0303645A priority Critical patent/HUP0303645A3/en
Priority to MXPA03009082A priority patent/MXPA03009082A/en
Priority to JP2002579493A priority patent/JP2005518183A/en
Priority to KR10-2003-7013263A priority patent/KR20030094336A/en
Priority to EP02722021A priority patent/EP1412382A2/en
Priority to CA002443277A priority patent/CA2443277A1/en
Priority to IL15789602A priority patent/IL157896A0/en
Priority to BR0208596-8A priority patent/BR0208596A/en
Application filed by Maxygen Holdings Ltd, Anne Dam Jensen filed Critical Maxygen Holdings Ltd
Priority to AU2002252971A priority patent/AU2002252971B2/en
Priority to NZ528651A priority patent/NZ528651A/en
Publication of WO2002081507A2 publication Critical patent/WO2002081507A2/en
Priority to NO20034432A priority patent/NO20034432L/en
Publication of WO2002081507A3 publication Critical patent/WO2002081507A3/en
Priority to HK05102256A priority patent/HK1069834A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly beter utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variatns when administered subcutaneously.
PCT/DK2002/000226 2001-04-06 2002-04-04 Interferon gamma polypeptide variants WO2002081507A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL15789602A IL157896A0 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
JP2002579493A JP2005518183A (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variant
KR10-2003-7013263A KR20030094336A (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
EP02722021A EP1412382A2 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
CA002443277A CA2443277A1 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
HU0303645A HUP0303645A3 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
BR0208596-8A BR0208596A (en) 2001-04-06 2002-04-04 Interferon gamma (ifng) polypeptide variant, nucleotide sequence, expression vector, glycosylation host cell, population of ifng polypeptide variants or a composition, pharmaceutical composition, use of a polypeptide variant, and methods for the treatment of interstitial lung diseases, for increasing the degree of in vivo n-glycosylation of a polypeptide with parental ifng, and for the production of a polypeptide variant with ifng
MXPA03009082A MXPA03009082A (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants.
AU2002252971A AU2002252971B2 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants
NZ528651A NZ528651A (en) 2001-04-06 2002-04-04 Glycosylated interferon gamma polypeptide variants
NO20034432A NO20034432L (en) 2001-04-06 2003-10-03 Interferon gamma polypeptide variants
HK05102256A HK1069834A1 (en) 2001-04-06 2005-03-15 Interferon gamma polypeptide variants

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200100579 2001-04-06
DKPA200100579 2001-04-06
DKPA200100714 2001-05-07
DKPA200100714 2001-05-07
DKPA200200198 2002-02-11
DKPA200200198 2002-02-11

Publications (2)

Publication Number Publication Date
WO2002081507A2 WO2002081507A2 (en) 2002-10-17
WO2002081507A3 true WO2002081507A3 (en) 2004-02-12

Family

ID=27222504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000226 WO2002081507A2 (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants

Country Status (15)

Country Link
EP (1) EP1412382A2 (en)
JP (1) JP2005518183A (en)
KR (1) KR20030094336A (en)
CN (1) CN1257186C (en)
BG (1) BG108256A (en)
BR (1) BR0208596A (en)
CA (1) CA2443277A1 (en)
HK (1) HK1069834A1 (en)
HU (1) HUP0303645A3 (en)
IL (1) IL157896A0 (en)
MX (1) MXPA03009082A (en)
NO (1) NO20034432L (en)
NZ (1) NZ528651A (en)
PL (1) PL366705A1 (en)
WO (1) WO2002081507A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446821C2 (en) * 2010-07-15 2012-04-10 Олег Ильич Эпштейн Drug preparation for treating infectious diseases accompanied by neurotoxic disorders, and method of treating infectious diseases accompanied by neurotoxic disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525188A (en) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド Synthetic chemokine receptor ligands and methods of use thereof
JP4707327B2 (en) * 2004-01-27 2011-06-22 旭化成ファーマ株式会社 Polypeptides adsorption inhibitors
JP2008513356A (en) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． Synthetic advanced glycosylated protease resistant polypeptide variants, oral formulations and methods using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN103550757A (en) * 2005-09-20 2014-02-05 纽约大学 Method for treating lung diseases by using interferon
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
JP5769142B2 (en) * 2007-09-04 2015-08-26 独立行政法人酒類総合研究所 Method for high secretion of heterologous proteins in Pichia yeast
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
BG66517B1 (en) 2008-04-08 2016-02-29 Tigo Gmbh Inhibitor of endogenous human interferon - gamma
BG67190B1 (en) 2017-03-29 2020-11-16 Tigo Gmbh Anti-gama mutant protein against endogenous human gamma interferon
WO2023182947A1 (en) * 2022-03-22 2023-09-28 Chiang Mai University A modified protein of interferon gamma and its use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0446582A1 (en) * 1990-01-24 1991-09-18 Pharmagen Ltd. Method for producing of recombinant human cysteineless gamma-interferon free of methionine at n-terminal
WO1992008737A1 (en) * 1990-11-19 1992-05-29 Dr. Rentschler Arzneimittel Gmbh & Co. NEW HUMAN RECOMBINANT η INTERFERON
US5690925A (en) * 1983-12-16 1997-11-25 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690925A (en) * 1983-12-16 1997-11-25 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
EP0446582A1 (en) * 1990-01-24 1991-09-18 Pharmagen Ltd. Method for producing of recombinant human cysteineless gamma-interferon free of methionine at n-terminal
WO1992008737A1 (en) * 1990-11-19 1992-05-29 Dr. Rentschler Arzneimittel Gmbh & Co. NEW HUMAN RECOMBINANT η INTERFERON

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL JOURNAL, vol. 303, no. 3, 1994, pages 831 - 840, ISSN: 0264-6021 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, SARENEVA TIMO ET AL: "Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-gamma.", XP002225748, Database accession no. PREV199598030544 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446821C2 (en) * 2010-07-15 2012-04-10 Олег Ильич Эпштейн Drug preparation for treating infectious diseases accompanied by neurotoxic disorders, and method of treating infectious diseases accompanied by neurotoxic disorders

Also Published As

Publication number Publication date
PL366705A1 (en) 2005-02-07
HK1069834A1 (en) 2005-06-03
CN1537117A (en) 2004-10-13
NO20034432L (en) 2003-10-29
BG108256A (en) 2004-12-30
HUP0303645A3 (en) 2005-12-28
MXPA03009082A (en) 2004-11-22
HUP0303645A2 (en) 2004-01-28
KR20030094336A (en) 2003-12-11
IL157896A0 (en) 2004-03-28
JP2005518183A (en) 2005-06-23
NZ528651A (en) 2006-06-30
EP1412382A2 (en) 2004-04-28
NO20034432D0 (en) 2003-10-03
WO2002081507A2 (en) 2002-10-17
BR0208596A (en) 2004-03-09
CN1257186C (en) 2006-05-24
CA2443277A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
KR100854198B1 (en) 21 muteins of fibroblast growth factor 21
KR101873773B1 (en) Composition for preventing or treating rheumatoid arthritis
WO2005019256A3 (en) Muteins of tear lipocalin
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
DK0950096T3 (en) Anti-invasive and anti-angiogenic urokinase fragments and their use
WO2002020766A3 (en) G-csf analog compositions and methods
WO2002022776A3 (en) Human coagulation factor vii variants
WO2002081507A3 (en) Interferon gamma polypeptide variants
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
JP2008522617A5 (en)
UA91820C2 (en) Therapeutic uses of chemokine variants
NO20060675L (en) Enhanced recombinant human interferon beta-lb polypeptides
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
DE60115475T2 (en) VARIANTS OF THE DERMATOPHAGOIDES ALLERGENS OF p 2
WO2004005341A3 (en) Full-length interferon gamma polypeptide variants
DE10033195A1 (en) Bifunctional fusion proteins from hirudin and TAP
DE60110096T2 (en) VARIANTS OF THE ALLERGENIC PROTEIN PHL P 1 FROM PHLEUM PRATENSE
AU625787B2 (en) Stabilized, potent grf analogs
CA2211413A1 (en) Human dnase i variants
WO2001053324A8 (en) Novel haptotactic peptides
EP4008341A1 (en) Cra4s1 gene, encoded cra4s1 protein, and application
JP2004505616A5 (en)
WO2006067469A3 (en) Compositions comprising opa protein epitopes
AU2002326742B2 (en) KGF polypeptide compositions
Yamasaki et al. Purification and characterization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derivatives: KW-2228 and other derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 157896

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002252971

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009082

Country of ref document: MX

Ref document number: 528651

Country of ref document: NZ

Ref document number: 2443277

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002579493

Country of ref document: JP

Ref document number: 1020037013263

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 028078918

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 10825602

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002722021

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/08376

Country of ref document: ZA

Ref document number: 200308376

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1714/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2003-3016

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-3016

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002722021

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002252971

Country of ref document: AU

Date of ref document: 20020404

Kind code of ref document: B